Sanjai Rao, MD: Long-Acting Injectables for Schizophrenia
Treatment adherence remains a concern in psychiatry.
John J. Miller, MD: A New Era For Psychiatric Medications
The FDA approved esketamine in 2019 for major depressive disorder.
Anita Clayton, MD: Women's Issues in Psychiatry
Postpartum depression rates have increased since the COVID-19 pandemic.
Michael Thase, MD: Risk Factors for Chronically Depressed Patients
Alcohol, stress, drug use, and not seeking help are all risk factors for chronic depression.
John J. Miller, MD: Guidance on Cannabis Use in Psychiatry
CBD has shown promise in treating anxiety and psychosis.
Christopher Schneck, MD: Early Interventions for Bipolar Disorder
There remains a need for better treatments for bipolar disorder when it is identified early.
Joseph Goldberg, MD: Treating Mixed Feature Depression
Mixed feature depression can be difficult to diagnose because the symptoms can be similar to other psychiatric disorders.
M. Katherine Shear, MD: Addressing Grief After a Loss
There remains a need for more research into the connection between grief and depression following a death.
Larry Culpepper, MD: The Challenge of Treating BPD
Borderline personality disorder remains one of the most difficult to understand conditions in psychiatry.
Michael Thase, MD: New Medications for Treatment-Resistant Depression
Esketamine is seen as a major breakthrough in finding more treatments for depression.
M. Katherine Shear, MD: Bereavement and Depression
Dr. Shear talked about the similarities and differences between depression and grief and the importance of recognizing both.
2 Clarke Drive Cranbury, NJ 08512